Geode Capital Management
PYXS icon

Geode Capital Management’s Pyxis Oncology PYXS Stock Holding History

Geode Capital Management’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$874K Buy
598,121
+20,910
+4% +$31.5K ﹤0.01% 3397
2025
Q4 		$664K Buy
577,211
+32,703
+6% +$115K ﹤0.01% 3501
2025
Q3 		$1.21M Buy
544,508
+33,545
+7% +$48.3K ﹤0.01% 3323
2025
Q2 		$562K Sell
510,963
-598,135
-54% -$674K ﹤0.01% 3516
2025
Q1 		$1.09M Buy
1,109,098
+26,649
+2% +$35.6K ﹤0.01% 3279
2024
Q4 		$1.69M Sell
1,082,449
-2,278
-0.2% -$6.57K ﹤0.01% 3194
2024
Q3 		$3.98M Buy
1,084,727
+57,016
+6% +$200K ﹤0.01% 2883
2024
Q2 		$3.4M Buy
1,027,711
+687,590
+202% +$2.89M ﹤0.01% 2927
2024
Q1 		$1.45M Buy
340,121
+31,880
+10% +$134K ﹤0.01% 3234
2023
Q4 		$555K Buy
308,241
+19,942
+7% +$34.2K ﹤0.01% 3567
2023
Q3 		$574K Buy
288,299
+45,512
+19% +$105K ﹤0.01% 3546
2023
Q2 		$622K Buy
242,787
+3,436
+1% +$10.9K ﹤0.01% 3559
2023
Q1 		$960K Buy
239,351
+35,417
+17% +$70.7K ﹤0.01% 3367
2022
Q4 		$273K Buy
203,934
+15,113
+8% +$22.7K ﹤0.01% 3935
2022
Q3 		$371K Buy
188,821
+78,974
+72% +$206K ﹤0.01% 3887
2022
Q2 		$261K Sell
109,847
-84,730
-44% -$226K ﹤0.01% 4109
2022
Q1 		$786K Buy
194,577
+13,105
+7% +$95.8K ﹤0.01% 3720
2021
Q4 		$1.99M Buy
+181,472
New +$2.08M ﹤0.01% 3361

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

Geode Capital Management's PYXS Position: Q1 2026 in Review

Geode Capital Management increased its Pyxis Oncology (PYXS) stake by 3.6% in Q1 2026, buying an estimated $31.5K and bringing the position to 598,121 shares worth $874K. The position accounts for ﹤0.01% of the portfolio, ranked #3397.

Geode Capital Management first reported a position in PYXS in Q4 2021 and has held it in 18 quarters since. The position peaked at $3.98M in Q3 2024. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Geode Capital Management held 598,121 shares of Pyxis Oncology worth $874K as of Q1 2026.
  • Geode Capital Management bought 20,910 Pyxis Oncology shares in Q1 2026, an estimated $31.5K.
  • Pyxis Oncology made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3397 holding.
  • Geode Capital Management first reported a position in Pyxis Oncology in Q4 2021 and has held it in 18 quarters since.
  • Geode Capital Management's Pyxis Oncology position peaked at $3.98M in Q3 2024.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.